Market Pulse
Sunday newspaper round-up: AstraZeneca, oil IPOs, M&S, Exova, Tesco
AstraZeneca, the UK's second-biggest drug developer, will this week outline its next big hope in the battle against cancer by unveiling new data on a class of treatments, known as DNA damage response (DDR) medicines, at a conference in Chicago. The drugs work by stopping cancerous cells repairing themselves, in effect by blocking them from attracting the proteins needed to regenerate, as well as proving much less damaging to the body than chemotherapy.
Sunday share tips: Flybe, United Utilities, FairFX
Sell shares in Flybe, was the verdict of the Sunday Times' Inside the City column as prospects for profits look limited. A week and a half away from full year results, shares in the regional airline are flying at 53. 5p, half the level they started 2015 and valuing the company at a £55m discount to its solid cash pile. Boss Saad Hammad was helicopetered from his role as chief commercial officer at EasyJet in summer 2013, with the shares at 47p and a pledge to pilot Flybe to a "new and exciting" era.